09:10 AM EDT, 06/04/2024 (MT Newswires) -- Health care stocks were steady pre-bell Tuesday, with the Health Care Select Sector SPDR Fund ( XLV ) and iShares Biotechnology ETF ( IBB ) each recently inactive.

Annexon ( ANNX ) rallied more than 37% after saying its phase 3 trial evaluating investigational monoclonal antibody ANX005 in patients with the neurological disease Guillain-Barre syndrome met its primary endpoint and showed early and sustained improvements in key secondary endpoints.

BridgeBio Pharma ( BBIO ) advanced more than 8% after saying its group 5 dose escalation in a phase 2 trial of infigratinib, an investigational therapy to treat children with achondroplasia, a growth deficiency, is showing a "continued well-tolerated safety profile."

Viking Therapeutics ( VKTX ) was more than 2% higher after it reported "positive" 52-week data from its phase 2b study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis.